Relevant bibliographies by topics / Drug control – Health aspects – Canada

Academic literature on the topic 'Drug control – Health aspects – Canada'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Drug control – Health aspects – Canada.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Drug control – Health aspects – Canada"

1

Lofgren, Hans. "Medicines policy and drug company investments: the Irish experience." Australian Health Review 33, no. 2 (2009): 295. http://dx.doi.org/10.1071/ah090295.

Full text
Abstract:
THIS BOOK IS ABOUT MANIFESTATIONS of power in medicines and pharmaceutical industry policy. The main focus is on the Republic of Ireland but there are chapters also on drug regulation in Canada, Britain and Australia. The multinational pharma companies loom larger in Ireland than in most other countries; several chapters detail the implications for this small country of the presence of a major cluster of global drug companies. Globalisation is the hallmark of the drug sector; innovation and production occur within international networks which are mirrored by interaction between regulatory agencies which operate similar systems of control and monitoring. Since the 1990s, many aspects of product safety regulation have been standardised across the developed countries through the International Conference on Harmonization (ICH) process, sponsored by the regulatory agencies and industry associations of the USA, the European Union and Japan. While orchestrating vast scientific, economic and technological resources, the big pharma companies participate as insiders in national policy processes, such as those described in this book. Firms typically affirm a commitment to the health and economic concerns of the local jurisdiction ? however governments cannot help but be sensitive to their global reach and power to choose where to invest.
APA, Harvard, Vancouver, ISO, and other styles
2

Aliyeva, Zamina. "The Law Aspects in Health Management: A Bibliometric Analysis of Issues on the Injury, Damage and Harm in Criminal Law." Marketing and Management of Innovations, no. 3 (2020): 293–305. http://dx.doi.org/10.21272/mmi.2020.3-21.

Full text
Abstract:
The paper presents the analysis of the approaches to define the areas of research on the injury, damage and harm to human health in criminal law. The obtained results proved that crimes, connected to drugs abuse, their legislation become an essential part of the issues. At the same, developing of government control, medical standards, improving quality of medical education balancing the «medical mistake – injury to human’s health – jurisprudence consequences» triangle in the tendency of the injury, damage and harm in criminal laware becoming very important to the healthcare system due to increasing requirements of regulators, customers and shareholders. The paper aimed to analyse the tendency in the literature on the injury, damage and harm in criminal law, which published in books, journals, conference proceedings etc. to identify future research directions. The methodological tools are VOSviewer, Scopus and Web of Science (WoS) software. This study covers 1072 papers from Scopus and WoS database. The time for analysis were 1970-2020. The Scopus and WoS analyse showed that in 2012-2019 the numbers of papers on the injury, damage and harm in criminal law issues began to increase. However, the topics changed from general issues to the problem of decriminalisation of drug trafficking, and the corresponding paradigm shift in the punishment of some crimes, increasing interest in punishing corporations for violating environmental regulations. In 2017 the number of documents dedicated to injury, damage and harm in criminal law was increased by 667% compared to 2012. The main subject areas of analyses of the injury, damage and harm in criminal law were the next: Law, Public environmental, occupational health, Criminology penology, Substance abuse, Psychiatry, Medicine. The biggest amount of investigations of the injury, damage and harm in criminal law was published by the scientists from the USA, United Kingdom, Australia and Canada. In 2019 such journals with high impact factor as International Journal of Drug Policy, International Journal of Law and Psychiatry, The Lancet etc. published the number of issues, which analysed of the injury, damage and harm to human health in criminal law. Such results proved that theme on the injury, damage and harm to human health in criminal law is actually in the ongoing trends of the modern jurisprudence and regulation. The findings from VOSviewer defined 6 clusters of the papers which analysed the injury, damage and harm to human health in criminal law from the different points of views. The first biggest cluster (with the biggest number of connections) merged the keywords as follows: criminal justice, law enforcement, public health, health care policy, harm reduction, drug legislation, drug and narcotic control, substance abuse, homelessness etc. The second significant cluster integrated the keywords as follows: criminal behaviour, crime victim, adolescent, violence, mental health, mental disease, prisoner, young people, rape, police etc. The third biggest cluster concentrated on criminal aspects of jurisprudence, criminal law, human right, legal liability, social control, government regulation etc. The obtained results allow concluding that balancing the triangles «medical mistakes – criminal – education» and «drugs – criminal – justice» and «abortion – criminal – women/children» form an important part of the injury, damage and harm in criminal law issues. Keywords injury, damage, harm, human health, criminal law, management, governance.
APA, Harvard, Vancouver, ISO, and other styles
3

Matsuhama, Maki, Tomoko Takishita, Ryosuke Kuribayashi, Kazunori Takagi, Rika Wakao, and Kenichi Mikami. "Similarities and Differences of International Practices and Procedures for the Regulation for Active Substance Master Files/Drug Master Files of Human Use: Moving Toward Regulatory Convergence." Journal of Pharmacy & Pharmaceutical Sciences 19, no. 2 (August 8, 2016): 290–300. http://dx.doi.org/10.18433/jpps.v19i2.27066.

Full text
Abstract:
Purpose. A gap analysis survey of international practices for Active Substance Master Files (ASMFs)/Drug Master Files (DMFs) of human use was conducted as a project of the ASMF/DMF working group of the International Generic Drug Regulators Pilot (IGDRP) to identify similarities and differences among ASMF/DMF procedures of 10 IGDRP members and 2 observers. Methods. We conducted a questionnaire survey and compared the following aspects: overall ASMF/DMF procedures, submission requirements for ASMFs/DMFs, assessment processes for ASMFs/DMFs, the technical requirements for active pharmaceutical ingredients (APIs), generation of assessment reports for ASMFs/DMFs, procedures for changing ASMF/DMF details, and Good Manufacturing Practice (GMP) inspection/certification of API manufacturers. Twelve organizations participated in this project: the Brazilian Health Surveillance Agency (Anvisa), the European Union (EU), Health Canada (HC), the Singapore Health Sciences Authority (HSA), the South African Medicines Control Council (MCC), the South Korean Ministry of Food and Drug Safety (MFDS), the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), the Swiss Agency for Therapeutic Products (Swissmedic), the Taiwan Food and Drug Administration (TFDA), the Australian Therapeutic Goods Administration (TGA), the European Directorate for the Quality of Medicines & HealthCare (EDQM) (Observer) and the Prequalification Team (PQT) of the World Health Organization (WHO), which includes the PQT–Medicines (Observer). Results. Although there were many similarities among the participating agencies surveyed, there were also differences that should be discussed such as assessment processes of ASMFs/DMFs and Technical requirements for APIs. Conclusions. These differences revealed by this survey will be key considerations in order to facilitate the filing of ASMFs/DMFs globally and to establish a framework for sharing and utilizing information related to ASMFs/DMFs among IGDRP members in the future. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.
APA, Harvard, Vancouver, ISO, and other styles
4

Matsuhama, Maki, Tomoko Takishita, Ryosuke Kuribayashi, Kazunori Takagi, Rika Wakao, and Kenichi Mikami. "Similarities and Differences of International Practices and Procedures for the Regulation for Active Substance Master Files/Drug Master Files of Human Use: Moving Toward Regulatory Convergence." Journal of Pharmacy & Pharmaceutical Sciences 19, no. 2 (August 8, 2016): 290. http://dx.doi.org/10.18433/j37g80.

Full text
Abstract:
Purpose. A gap analysis survey of international practices for Active Substance Master Files (ASMFs)/Drug Master Files (DMFs) of human use was conducted as a project of the ASMF/DMF working group of the International Generic Drug Regulators Pilot (IGDRP) to identify similarities and differences among ASMF/DMF procedures of 10 IGDRP members and 2 observers. Methods. We conducted a questionnaire survey and compared the following aspects: overall ASMF/DMF procedures, submission requirements for ASMFs/DMFs, assessment processes for ASMFs/DMFs, the technical requirements for active pharmaceutical ingredients (APIs), generation of assessment reports for ASMFs/DMFs, procedures for changing ASMF/DMF details, and Good Manufacturing Practice (GMP) inspection/certification of API manufacturers. Twelve organizations participated in this project: the Brazilian Health Surveillance Agency (Anvisa), the European Union (EU), Health Canada (HC), the Singapore Health Sciences Authority (HSA), the South African Medicines Control Council (MCC), the South Korean Ministry of Food and Drug Safety (MFDS), the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), the Swiss Agency for Therapeutic Products (Swissmedic), the Taiwan Food and Drug Administration (TFDA), the Australian Therapeutic Goods Administration (TGA), the European Directorate for the Quality of Medicines & HealthCare (EDQM) (Observer) and the Prequalification Team (PQT) of the World Health Organization (WHO), which includes the PQT–Medicines (Observer). Results. Although there were many similarities among the participating agencies surveyed, there were also differences that should be discussed such as assessment processes of ASMFs/DMFs and Technical requirements for APIs. Conclusions. These differences revealed by this survey will be key considerations in order to facilitate the filing of ASMFs/DMFs globally and to establish a framework for sharing and utilizing information related to ASMFs/DMFs among IGDRP members in the future. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.
APA, Harvard, Vancouver, ISO, and other styles
5

Scanlon, Martin N., and Urmil Chugh. "Exploring Physicians' Comfort Level with Opioids for Chronic Noncancer Pain." Pain Research and Management 9, no. 4 (2004): 195–201. http://dx.doi.org/10.1155/2004/290250.

Full text
Abstract:
OBJECTIVE:To explore the attitudes of family physicians (FPs) toward the use of opioids in the management of chronic noncancer pain (CNCP) in the Calgary Health Region (CHR), Calgary, Alberta.METHODS:From January to February 2003, random samples of 147 FPs (32 were used to pretest the instrument and were therefore excluded from the findings) and 142 specialists practicing in the CHR were invited to participate in a 20 min survey to explore aspects of CNCP management in the CHR. Physicians' comfort in prescribing opioids and nonsteroidal anti-inflammatory drugs for CNCP was measured on a four-point ordinal scale. The specialists' subgroup served as a quasi-control group. In addition, a short version of the survey was provided for those physicians who declined to fully partake in the study. This allowed the researchers to compare important characteristics between respondents and nonrespondents.RESULTS:A total of 125 physicians (63 FPs and 62 specialists) participated in the study. The overall response rate was 48.6% and response rates for FPs and specialists were 54.8% and 43.7%, respectively. Response rates for the long version of the survey were 42.6% for FPs (n=49), 31.6% for other specialists (n=45) and 36.6% for both combined. The majority of FPs and specialists (98% and 71.1%, respectively) reported that 'they can handle' nonsteroidal anti-inflammatory drugs, Tylenol No 3 with Codeine (Janssen-Ortho/McNeil Consumer Healthcare, Canada) (95.9% and 64.4%, respectively), morphine/MS Contin (Purdue Pharma, Canada) (61.2% and 24.4%, respectively) and Percocet (Bristol-Myers Squibb, Canada)/OxyContin (Purdue Pharma, Canada) (61.2% and 33.3%, respectively). Fewer FPs and specialists report that 'they can handle' Dilaudid (Abbott Laboratories, Canada)/Hydromorph Contin (Purdue Pharma, Canada) (36.7% and 13.3%, respectively), fentanyl patch (30.6% and 11.1%, respectively) and methadone (0% and 6.7%, respectively). Male FPs reported a greater degree of comfort than female FPs regarding morphine/MS Contin, Percocet/OxyContin and Dilaudid/Hydromorph Contin (Mann-Whitney U tested at a£0.05). No sex differences were detected among specialists. No relationship was detected between comfort and years of practice or number of chronic pain patients in practice. Among specialists, a weak positive relationship was detected between the degree of comfort with methadone (Spearman's rank correlation coefficient=0.35, a=0.03) and the significance of pain management in the practice. Except for methodone, the FPs reported a higher confidence with the drugs in question compared with specialists (a£0.05).CONCLUSIONS:FPs in the CHR need to increase their comfort level toward opioids in general to adequately manage CNCP. Their lack of comfort may reflect a lack of education or fear of regulatory scrutiny.
APA, Harvard, Vancouver, ISO, and other styles
6

Phypers, Melissa D., Linda Panaro, and Penny Nault. "Tuberculosis drug resistance in Canada, 1998 to 2000." Canadian Journal of Infectious Diseases 12, no. 3 (2001): 141–43. http://dx.doi.org/10.1155/2001/148487.

Full text
Abstract:
The emergence of drug-resistant strains of tuberculosis (TB) is a global threat to TB prevention and control efforts. A recent study conducted by the World Health Organization (WHO) and the International Union Against Tuberculosis and Lung Disease found strains of TB resistant to first-line anti-TB drugs in all countries surveyed (1). The WHO estimates that 50 million people are infected with strains of drug-resistant TB (2).
APA, Harvard, Vancouver, ISO, and other styles
7

Barrett, Damon. "Canada, cannabis and the relationship between UN child rights and drug control treaties." International Journal of Drug Policy 71 (September 2019): 29–35. http://dx.doi.org/10.1016/j.drugpo.2019.02.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ostry, Aleck S. "International Trade Regulation and Publicly Funded Health Care in Canada." International Journal of Health Services 31, no. 3 (July 2001): 475–80. http://dx.doi.org/10.2190/mt8d-h4ec-jkme-3kd3.

Full text
Abstract:
The World Trade Organization (WTO) creates new challenges for the Canadian health care system, arguably one of the most “socialized” systems in the world today. In particular, the WTO's enhanced trade dispute resolution powers, enforceable with sanctions, may make Canadian health care vulnerable to corporate penetration, particularly in the pharmaceutical and private health services delivery sectors. The Free Trade Agreement and its extension, the North American Free Trade Agreement, gave multinational pharmaceutical companies greater freedom in Canada at the expense of the Canadian generic drug industry. Recent challenges by the WTO have continued this process, which will limit the health care system's ability to control drug costs. And pressure is growing, through WTO's General Agreement on Trade in Services and moves by the Alberta provincial government to privatize health care delivery, to open up the Canadian system to corporate penetration. New WTO agreements will bring increasing pressure to privatize Canada's public health care system and limit government's ability to control pharmaceutical costs.
APA, Harvard, Vancouver, ISO, and other styles
9

Egilman, Alexander C., Amy Kapczynski, Margaret E. McCarthy, Anita T. Luxkaranayagam, Christopher J. Morten, Matthew Herder, Joshua D. Wallach, and Joseph S. Ross. "Transparency of Regulatory Data across the European Medicines Agency, Health Canada, and US Food and Drug Administration." Journal of Law, Medicine & Ethics 49, no. 3 (2021): 456–85. http://dx.doi.org/10.1017/jme.2021.67.

Full text
Abstract:
AbstractBased on an analysis of relevant laws and policies, regulator data portals, and information requests, we find that clinical data, including clinical study reports, submitted to the European Medicines Agency and Health Canada to support approval of medicines are routinely made publicly available.
APA, Harvard, Vancouver, ISO, and other styles
10

Price, Polly J. "Public Health Control Measures in Response to Global Pandemics and Drug Resistance." Journal of Law, Medicine & Ethics 43, S2 (2015): 49–56. http://dx.doi.org/10.1111/jlme.12266.

Full text
Abstract:
These teaching materials explore the specific powers of governments to implement control measures in response to communicable disease, in two different contexts:The first context concerns global pandemic diseases. Relevant legal authority includes international law, World Health Organization governance and the International Health Regulations, and regulatory authority of nations.The second context is centered on U.S. law and concerns control measures for drug-resistant disease, using tuberculosis as an example. In both contexts, international and domestic, the point is to understand legal authority to address public health emergencies.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Drug control – Health aspects – Canada"

1

Locke, Tiffany. "Methicillin-resistant Staphylococcus Aureus in Canadian Hospitals from 1995 to 2007: A Comparison of Adult and Pediatric Inpatients." Thèse, Université d'Ottawa / University of Ottawa, 2013. http://hdl.handle.net/10393/26110.

Full text
Abstract:
The literature directly comparing the epidemiology of MRSA among adult and pediatric hospitalized patients is strikingly minimal. The objective of this thesis was to identify any differences between these two patient groups. The Canadian Nosocomial Infections Surveillance Program MRSA data (1995 to 2007: n=1,262 pediatric and 35,907 adult cases) were used to compare MRSA clinical and molecular characteristics and rates. Hospital characteristics were modeled using repeated measures Poisson regressions. The molecular and epidemiological characteristics of MRSA differed significantly between adults and children. Compared to children, MRSA in adults was more likely to be healthcare-associated, colonization, SCCmec type II, PVL negative, and resistant to most antibiotics. Rates of MRSA in Canada increased in both populations over time but were significantly higher in adults. The hospital characteristics associated with increased MRSA rates differed in adult and pediatric facilities. Implications for infection prevention and control strategies are discussed.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Drug control – Health aspects – Canada"

1

Canada. Health and Welfare Canada. Risk perception and drug safety evaluation. [Ottawa]: Health and Welfare Canada, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

The invisible drug. Houston: Mosaic Publications, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Committee, National Strategy to Reduce Tobacco Use in Canada Steering. New directions for tobacco control in Canada: A national strategy. [Ottawa, Ont: The Steering Committee, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Mazerolle, Lorraine Green. Controlling drug and disorder problems: Oakland's Beat Health Program. [Washington, DC]: U.S. Dept. of Justice, Office of Justice Programs, National Institute of Justice, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mazerolle, Lorraine Green. Controlling drug and disorder problems: Oakland's Beat Health Program. [Washington, DC]: U.S. Dept. of Justice, Office of Justice Programs, National Institute of Justice, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Brisson, Pierre. Prévention des toxicomanies: Aspects théoriques et méthodologiques. Montréal]: Les Presses de l'Université de Montréal, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Canada. Minister of Public Works and Government Services Canada. The national strategy: Moving forward : the 2004 progress report on tobacco control. Ottawa: Health Canada, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mintzes, Barbara. Direct-to-consumer advertising of prescription drugs in Canada: What are the public health implications? Toronto: Health Council of Canada, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mintzes, Barbara. Direct-to-consumer advertising of prescription drugs in Canada: What are the public health implications? Toronto, Ont: Health Council of Canada, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Canada. Minister of Public Works and Government Services Canada. The national strategy: Moving forward : the 2001 federal provincial territorial progress report on tobacco control. Ottawa: Minister of Public Works and Government Services Canada, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Drug control – Health aspects – Canada"

1

Littmann, Jasper, A. M. Viens, and Diego S. Silva. "The Super-Wicked Problem of Antimicrobial Resistance." In Ethics and Drug Resistance: Collective Responsibility for Global Public Health, 421–43. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-27874-8_26.

Full text
Abstract:
Abstract Antimicrobial resistance (AMR) – the progressive process by which microbes, such as bacteria, through evolutionary, environmental and social factors develop the ability to become resistant to drugs that were once effective at treating them – is a threat from which no one can escape. It is one of the largest threats to clinical and global health in the twenty-first century – inflicting monumental health, economic and social consequences. All persons locally and globally, and even all future persons yet to come into existence, all suffer the shared, interdependent vulnerability to this threat that will have a substantial impact on all aspects of our lives. For example, while reliable data are hard to find, the European Centre for Disease Prevention and Control (ECDC) has conservatively estimated that, in Europe alone, AMR causes additional annual cost to health care systems of at least €1.5 billion, and is responsible for around 25,000 deaths per year. Furthermore, AMR significantly increases the cost of treating bacterial infections with an increase in length of hospital stays and average number of re-consultations, as well as the resultant lost productivity from increased morbidity. With a combined cost of up to $100 trillion to the global economy – pushing a further 28 million people into extreme poverty – this is one of the most pressing challenges facing the world. Most troublingly, if we do not succeed in diminishing the progression of AMR, there is the very real potential for it to threaten common procedures and treatments of modern medicine, including the safety and efficacy of surgical procedures and immunosuppressing chemotherapy. Some experts are warning that we may soon be ushering in a post-antibiotic area.
APA, Harvard, Vancouver, ISO, and other styles
2

Alves de Araújo, Sandra, Tatiane Aranha da Penha-Silva, Jaqueline Diniz Pinho, Marcelo de Souza Andrade, and Ana Lucia Abreu-Silva. "microRNAs: Are They Important in the Development of Resistance in Leishmaniasis?" In Leishmaniasis - General Aspects of a Stigmatized Disease. IntechOpen, 2022. http://dx.doi.org/10.5772/intechopen.101514.

Full text
Abstract:
Leishmaniasis is an infectious and parasitic disease of great importance in public health. Numerous studies indicate that biochemical and molecular mechanisms are factors that contribute to the emergence of antileishmanial drug resistance. Currently, miRNAs have been identified as targets for the invasion of pathogens to control the immune response and imply resistance to treatments. Considering the alarming growth in drug resistance, new possibilities for controlling leishmaniasis have been emerging. Natural compounds originating from medicinal plants are being increasingly explored as promising antileishmanial alternatives. The chapter aims to provide a brief review on mechanisms of action associated with traditional agents used to treat leishmaniasis, focusing mainly on molecular bases associated with the resistance of Leishmania spp. to current drugs and identifying the possible miRNAs involved in this process. In addition, we seek to describe some of the promising plant molecules that can be used as potential antileishmanial agents and their possible mechanisms of action.
APA, Harvard, Vancouver, ISO, and other styles
3

Chooramani, Gagan, and Pooja Singh. "Impact of Tuberculosis in Elderly Population." In Handbook of Research on Geriatric Health, Treatment, and Care, 326–38. IGI Global, 2018. http://dx.doi.org/10.4018/978-1-5225-3480-8.ch018.

Full text
Abstract:
The World Health Organization has declared that the spread of tuberculosis is a global emergency. Despite the implementation of strong tuberculosis-control initiatives by WHO, this highly infectious disease continues to affect all vulnerable populations, including the elderly population. Adverse social factors and poor living conditions also affect the elderly much more than the young. The clinical characteristics of tuberculosis in older adults can be unusual and may be confused with age-related illnesses. Various factors related to old age can also cause complications in the diagnosis, treatment, and disease outcomes for tuberculosis patients. The contributory factors may be poor memory, deafness, mental confusion, or impairment of speech. In addition, therapy for tuberculosis in elderly individuals is challenging because of the increased incidence of adverse drug reactions. Hence, understanding the impact of these substantial aspects will help to overcome the problem of tuberculosis in the elderly population.
APA, Harvard, Vancouver, ISO, and other styles
4

Chooramani, Gagan, and Pooja Singh. "Impact of Tuberculosis in Elderly Population." In Research Anthology on Supporting Healthy Aging in a Digital Society, 1415–27. IGI Global, 2022. http://dx.doi.org/10.4018/978-1-6684-5295-0.ch080.

Full text
Abstract:
The World Health Organization has declared that the spread of tuberculosis is a global emergency. Despite the implementation of strong tuberculosis-control initiatives by WHO, this highly infectious disease continues to affect all vulnerable populations, including the elderly population. Adverse social factors and poor living conditions also affect the elderly much more than the young. The clinical characteristics of tuberculosis in older adults can be unusual and may be confused with age-related illnesses. Various factors related to old age can also cause complications in the diagnosis, treatment, and disease outcomes for tuberculosis patients. The contributory factors may be poor memory, deafness, mental confusion, or impairment of speech. In addition, therapy for tuberculosis in elderly individuals is challenging because of the increased incidence of adverse drug reactions. Hence, understanding the impact of these substantial aspects will help to overcome the problem of tuberculosis in the elderly population.
APA, Harvard, Vancouver, ISO, and other styles
5

Mohammed Katagum, Yahaya, Hayati Binti Kadir Shahar, Faisal Bin Ibrahim, Anisah Baharom, and Rafee Baharudin. "Using an Educational Training Module to Increase Knowledge, Attitudes and Practices of Malaria among Medicine Vendors in Yobe, Nigeria." In Current Topics and Emerging Issues in Malaria Elimination. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.98512.

Full text
Abstract:
This training module focuses on providing basic guidance on the current recommended approaches regarding malaria basic information, signs/symptoms, case detection, treatment, referral, and effective prevention strategies. The module can be used for in-service training programs on malaria or to assist in improving other health educator’s work as well as serve as referral handbook for practicing health professionals. It can thus be used as a stand-alone training or together with modules dealing with other aspects of malaria control, prevention and elimination. The module uses a problem-solving approach to facilitate understanding and thereby motivate trainees on improved malaria case management. In essence, the training aims to generally improve the knowledge, attitudes and practices (KAP) of the most common handlers of malaria cases in this part of the world, the training module is then expected to improve services obtained by the majority of patients on malaria. On completion of training using this module, trainees will have acquired appreciable knowledge and skills on malaria basic-information, signs/symptoms, case detection/differentials, recommended drug treatment/appropriate dosing, indication for referral of complicated cases, effective prevention methods and the need to sensitise communities to stand up against malaria.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Drug control – Health aspects – Canada"

1

Deuel, L. E., and G. H. Holliday. "Evolution of Oil and Gas Waste/Soil Remediation Regulations." In ASME 2005 International Mechanical Engineering Congress and Exposition. ASMEDC, 2005. http://dx.doi.org/10.1115/imece2005-80460.

Full text
Abstract:
The meaningful United States regulation of onshore oil and gas field waste/soil commenced in the mid 1980’s in response to a series of state, federal, industry and international initiatives. Most initiatives centered on the design, construction and operation of earthen pits used in the exploration and production of oil and gas (E&P). Prior to this time, earthen pits were constructed as needed by the operator and used in all phases of E&P activity. Chief concerns of the regulators were focused on what had gone into pits historically, what was going into them currently and was the E&P exemption excluding high volume E&P wastes from the Resource Conservation and Recovery Act (RCRA) regulations justified. Several investigations, including the comprehensive field study by the Environmental Protection Agency in 1987, determined E&P wastes are ostensibly non-hazardous. EPA concluded regulation of E&P wastes under RCRA Subtitle C was not necessary. To this day there is no U. S. federal regulatory program with exclusive jurisdiction over exempt E&P wastes. Other studies, primarily industry and academic, focusing on land limiting constituents, management practices and pit closure strategies revealed sodium salts and petroleum hydrocarbon in the form of diesel range organics were the primary limiting constituents. One state, Louisiana, adopted the technical aspects of these studies and developed a comprehensive regulation known as Statewide Order 29-B, which was based on the concept of limiting constituents and defined post closure performance standards. These standards limited salinity, sodicity, total metals and total petroleum hydrocarbon (oil & grease) with values varying with respect to landform, land use and closure technique. Other states have adopted some of the concepts and criteria advanced under 29-B but none are as comprehensive. Obviously there is a need to control what goes into pits and how pits should be closed. The industry would best be served by adopting the concepts and standards set forth in the Louisiana 29-B regulation. A few of the provisions could be changed to make it more palatable to industry without sacrificing the protection afforded human and animal health, safety and the environment. Internationally, particularly countries in South America embraced USEPA protocol for testing characteristically hazardous wastes, but 1) without the framework to handle the relatively large volume of non-hazardous E&P waste generated and 2) no regulations or protocols for on-site waste management. Several operators, although partners with state owned oil companies, on their own volition, applied the concepts and standards under Louisiana’s 29-B to rainforests in South America and rice paddies in Indonesia. Canada and European oil and gas producing countries have developed stringent standards not based on science, which favor costly treatment technologies. Generally, these countries prohibit cost effective on-site waste management and closure techniques. This paper traces the evolution of waste/soil remediation within the United States and internationally. We trace the progress as a function of time; the impetus for regulation; and probable future controls.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Drug control – Health aspects – Canada' for particular source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography